WallStSmart

Edwards Lifesciences Corp (EW)vsInspireMD Inc (NSPR)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Edwards Lifesciences Corp generates 59971% more annual revenue ($6.51B vs $10.84M). EW leads profitability with a 15.4% profit margin vs 0.0%. EW earns a higher WallStSmart Score of 55/100 (C).

EW

Buy

55

out of 100

Grade: C

Growth: 4.0Profit: 8.0Value: 5.3Quality: 8.5
Piotroski: 3/9Altman Z: 4.48

NSPR

Avoid

28

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 6.7Quality: 6.5
Piotroski: 3/9Altman Z: -5.08
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

EWUndervalued (+68.9%)

Margin of Safety

+68.9%

Fair Value

$254.99

Current Price

$84.37

$170.62 discount

UndervaluedFair: $254.99Overvalued
NSPRUndervalued (+45.6%)

Margin of Safety

+45.6%

Fair Value

$3.17

Current Price

$0.79

$2.38 discount

UndervaluedFair: $3.17Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EW3 strengths · Avg: 9.3/10
Debt/EquityHealth
0.0710/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
4.4810/10

Safe zone — low bankruptcy risk

Operating MarginProfitability
29.8%8/10

Strong operational efficiency at 29.8%

NSPR2 strengths · Avg: 10.0/10
Price/BookValuation
1.2x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0610/10

Conservative balance sheet, low leverage

Areas to Watch

EW4 concerns · Avg: 2.8/10
PEG RatioValuation
1.924/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

P/E RatioValuation
51.6x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-25.4%2/10

Earnings declined 25.4%

NSPR4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$39.96M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : EW

The strongest argument for EW centers on Debt/Equity, Altman Z-Score, Operating Margin. Profitability is solid with margins at 15.4% and operating margin at 29.8%. Revenue growth of 13.6% demonstrates continued momentum.

Bull Case : NSPR

The strongest argument for NSPR centers on Price/Book, Debt/Equity.

Bear Case : EW

The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 51.6x leaves little room for execution misses.

Bear Case : NSPR

The primary concerns for NSPR are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

EW profiles as a mature stock while NSPR is a value play — different risk/reward profiles.

EW carries more volatility with a beta of 0.85 — expect wider price swings.

EW is growing revenue faster at 13.6% — sustainability is the question.

EW generates stronger free cash flow (585M), providing more financial flexibility.

Bottom Line

EW scores higher overall (55/100 vs 28/100), backed by strong 15.4% margins and 13.6% revenue growth. NSPR offers better value entry with a 45.6% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Edwards Lifesciences Corp

HEALTHCARE · MEDICAL DEVICES · USA

Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.

Visit Website →

InspireMD Inc

HEALTHCARE · MEDICAL DEVICES · USA

InspireMD, Inc., a medical device company, is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of coronary and vascular disease in Europe, Latin America, the Middle East, and Asia. The company is headquartered in Tel Aviv, Israel.

Want to dig deeper into these stocks?